VivoSeq
Oncology

Colorectal Cancer

759

Pipeline Programs↗

292

Active Trials↗

187

Companies Involved↗

Colorectal Cancer is a highly competitive landscape with 759 programs across 187 companies. The most active players are EMD Serono Research & Development Institute, Inc., Chongqing Precision Biotech Co., Ltd, Arrys Therapeutics. 44 therapies are approved with 118 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

80/100

Mech. Concentration

4/100

Completion Rate

73/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.

2 programs

Phase 1C

Chongqing Precision Biotech Co., Ltd

2 programs

Phase 1A

Arrys Therapeutics

2 programs

Phase 1D

Dragonboat Biopharmaceutical Company Limited

2 programs

Phase 1A

Amal Therapeutics

2 programs

Phase 1C

Celyad Oncology SA

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical47

Iohexol

GE Healthcare

Fosaprepitant

Merck & Co.

Necitumumab

Eli Lilly

Ketamine

Aultman Health Foundation

Lidocaine

MEDRx USA, Inc.

Phase 1134

Panobinostat

SecuraBio

Aldesleukin

Iovance Biotherapeutics, Inc.

Curcumin

Merck & Co.

Revumenib

Syndax Pharmaceuticals

Carboplatin

Avyxa

Phase 2416

Sotorasib

Amgen

Trastuzumab

Organon and Co

Tucatinib

Pfizer

Pyrotinib

Hengrui Therapeutics, Inc.

Hydroxychloroquine

Alnylam Pharmaceuticals

Phase 3118

Pembrolizumab

Merck & Co.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Floxuridine

Pfizer

Adalimumab

Celltrion

Approved44

Adagrasib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Entrectinib

Roche

Fruquintinib

Takeda

Osimertinib

AstraZeneca

Docetaxel

Avyxa

Analysis

Modality Breakdown

82%

Small molecule

698 of 852 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody10412%Cell therapy162%Vaccine142%Protein / enzyme91%Antibody–drug conjugate4<1%Peptide3<1%Other4<1%

Small molecule leads; the ring shows all 852 classified programs, each share of the total. Modality classified for 99% of 950 pipeline programs.

Analysis

Trial Status

1,084

clinical trials

Completed419 · 39%
Unknown status216 · 20%
Recruiting160 · 15%
Terminated109 · 10%
Not yet recruiting72 · 7%
Active, not recruiting54 · 5%
Other54 · 5%

Clinical Trials

Trial Activity

1084 trials

Early-Onset Colorectal Cancer: An Observational Retrospective and Prospective Multicenter Study
Recruiting·NNiguarda Hospital·N/A·NCT06965335·20 enrolled
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer
Recruiting·RRuijin Hospital·Phase 1·NCT07035002·29 enrolled
A Study of Initiation Timing of VTE Prevention After Colorectal Cancer Surgery
Recruiting·RRenJi Hospital·N/A·NCT06259149·914 enrolled
The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.
Recruiting·YYunnan Cancer Hospital·N/A·NCT06477991·22 enrolled
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06008054·376 enrolled
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT05630794·36 enrolled
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Recruiting·NNGM Biopharmaceuticals, Inc·Phase 2·NCT07033026·136 enrolled
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Recruiting·—·Phase 1·NCT06848465·9 enrolled
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
Recruiting·FFudan University·Phase 2·NCT06856187·119 enrolled
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
Recruiting·GGerman Cancer Research Center·Phase 1·NCT05999396·89 enrolled
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Recruiting·FFudan University·Phase 3·NCT05086614·2,500 enrolled
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06369259·33 enrolled
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
Recruiting·UUniversity College, London·Phase 2·NCT05197322·78 enrolled
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT06663839·25 enrolled
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
Recruiting·WWest China Hospital·Phase 1·NCT06545630·10 enrolled
Page 1 of 73

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)